drugset
drugset / Trial / NCT06875063

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

NCT06875063 ↗

Phase 1 Recruiting 45 enrolled The First Affiliated Hospital of Xiamen University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the safety and tolerability of GB5005 in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).

Timeline

Start
2026-04-30
Primary completion
2026-05-31
Completion
2027-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject GB5005 Cell therapy 1e+06 cells/kg Intravenous
Subject GB5005 Cell therapy 2e+06 cells/kg Intravenous
Subject GB5005 Cell therapy 3e+06 cells/kg Intravenous
Subject GB5005 Cell therapy 5e+06 cells/kg Intravenous

Indications

B-cell non-Hodgkin lymphoma